Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

